Skip to main content
Cathay Biotech Inc. logo

Cathay Biotech Inc. — Investor Relations & Filings

Ticker · 688065 ISIN · CNE100004447 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 753 across all filing types
Latest filing 2023-12-13 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 688065

About Cathay Biotech Inc.

https://www.cathaybiotech.com/

Cathay Biotech Inc. specializes in the research, development, and commercial-scale production of bio-based materials through synthetic biology and metabolic engineering. The company’s core portfolio features long-chain diacids (LCDA), bio-based pentanediamine, and high-performance bio-based polyamides, including the Terryl and Ecopent product lines. These materials are utilized across various applications such as automotive components, electronics, consumer goods, and specialized textiles. By leveraging biological manufacturing processes to replace traditional thermochemical methods, the company provides sustainable alternatives to petroleum-derived chemicals. Cathay Biotech focuses on delivering high-performance, low-carbon solutions that support the transition toward a circular economy and reduced environmental impact in global supply chains.

Recent filings

Filing Released Lang Actions
上海市锦天城律师事务所关于上海凯赛生物技术股份有限公司向特定对象发行股票之法律意见书
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter issued by a law firm regarding a specific issuance of A shares by Shanghai Kaisai Biotechnology Co., Ltd. in 2023. It extensively discusses the legal compliance, approvals, qualifications, and conditions related to the company's targeted share issuance. The document references relevant laws, regulatory approvals, shareholder meetings, and the company's corporate structure. It is not a financial report, earnings release, or management discussion, but a legal opinion related to a capital raising event. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length (15,000 characters) and detailed content confirm it is the actual legal opinion, not just an announcement or certification. Therefore, the appropriate classification is CAP with high confidence.
2023-12-13 Chinese
上海凯赛生物技术股份有限公司关于向特定对象发行A股股票申请获得上海证券交易所受理的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement from Shanghai Kaisai Biotechnology Co., Ltd. regarding the acceptance by the Shanghai Stock Exchange of their application for a targeted issuance of A-shares. It mentions the receipt of a notification from the exchange about the acceptance of the securities issuance application and states that the issuance is subject to further approval by the China Securities Regulatory Commission. The document is short (578 characters) and serves as an announcement of the acceptance and ongoing review process, not the actual issuance or detailed financial report. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2023-12-13 Chinese
中信证券股份有限公司及招商证券股份有限公司关于上海凯赛生物技术股份有限公司向特定对象发行股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" which translates to "Listing Sponsorship Letter" or "Sponsorship Document" related to a specific issuance of A shares by Shanghai Cathay Biotech Co., Ltd. It contains detailed information about the issuer, the issuance plan, financial data, risk factors, and regulatory compliance. The document is a formal application and sponsorship document for a specific share issuance to particular investors, including pricing, quantity, lock-up periods, and use of proceeds. This type of document is related to capital raising and financing activities, specifically a private placement or targeted issuance of shares. It is not an annual report, earnings release, or management report. It is not a proxy statement or voting results announcement. It is not a merger or acquisition document. It is not a regulatory filing or announcement of a report publication. The document is a detailed capital/financing update regarding a specific share issuance. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2023-12-13 Chinese
中信证券股份有限公司及招商证券股份有限公司关于上海凯赛生物技术股份有限公司向特定对象发行股票之发行保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as an "发行保荐书" (Issuance Sponsorship Letter) related to a specific issuance of A shares by Shanghai Cathay Biotech Co., Ltd. It contains detailed information about the underwriting, the issuer, shareholders, financial data, legal compliance, and regulatory approvals. The document is a formal sponsorship letter prepared by the underwriter (CITIC Securities) for a specific share issuance, including due diligence, legal and financial review, and recommendation for the issuance. It is not a general annual report, earnings release, or other financial report but a detailed capital/financing update related to a specific share issuance. The document length is substantial (15,000 characters), and it contains substantive financial and business information related to the issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-12-13 Chinese
上海凯赛生物技术股份有限公司向特定对象发行股票证券募集说明书（申报稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书" which translates to a "Prospectus" or "Offering Circular" for a specific issuance of A shares by Shanghai Cathay Biotech Inc. It contains detailed information about the issuance, including background, pricing, shareholder structure, use of proceeds, risk factors, and legal compliance. The document is lengthy (15,000 characters) and includes comprehensive financial and corporate information related to a capital raising event. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. It is not an announcement of a report, nor a full annual or interim report, but a detailed disclosure document for a specific financing event.
2023-12-13 Chinese
天健会计师事务所（特殊普通合伙）关于上海凯赛生物技术股份有限公司向特定对象发行股票的财务报告及审计报告
Audit Report / Information Classification · 100% confidence The document contains a detailed audit report including audit opinions, basis for audit opinions, key audit matters, and extensive financial statements and notes. It references the audit of financial statements for the fiscal year ending December 31, 2022, and includes detailed accounting policies and financial disclosures. The presence of an auditor's opinion, detailed financial statements, and notes confirms this is a full audit report. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the document is classified as an Audit Report / Information (AR).
2023-12-13 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.